Dr. Christopher Jones is a board-certified radiation oncologist who specializes in the use of ionizing radiation to treat cancer, focusing on tumors of the head and neck, prostate, and brain. He investigates optimal use of radiation therapy (radiotherapy) techniques including intensity modulated radiation therapy (IMRT), high-dose brachytherapy, and image-guided radiation therapy. Dr. Jones is a Principal Investigator for Radiation Therapy Oncology Group (RTOG) National Cancer Institute-sponsored oncology group clinical trials. He has authored numerous publications and abstracts on radiotherapy and imaging techniques to assess cancer progression, predict tumor recurrence after surgery and radiotherapy, and visualize response to treatment. Dr. Jones lectures nationally and internationally on the role of radiation therapy in the management of head and neck cancers.
Sutter Health Research Enterprise
2800 L Street, #10
Sacramento, CA, 95816
(916) 454-6600
simr@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Adjuvant (N0577) (CODEL)
Radiation Therapy With Concomitant and Adjuvant Temozolomide VS Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic or Low Grade Glioma
Investigator: Christopher Jones MD
Status: Active, Recruiting
Adjuvant (NRG BN003)
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Investigator: Christopher Jones MD
Status: Active, Recruiting
First Line or Neoadjuvant (NRG-HN005) Temporary Hold
De-intensified Radiation Therapy With Cisplatin or Nivolumab in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Investigator: Christopher Jones MD
Status: Active, Not Recruiting
Interventional (HERO NRG-BR008)
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Interventional (NRG-GU009)
The PREDICT-RT Trial
Investigator: Christopher Jones MD
Status: Active, Recruiting
Interventional (NRG-GU010)
GUIDANCE Study
Investigator: Christopher Jones MD
Status: Active, Recruiting
Interventional (NRG-GU012) (SAMURAI)
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Interventional (NRG-LU007)
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG BN010)
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG BN011)
Testing Addition of Chemo Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and RT) for Newly Diagnosed MGMT Methylated Glioblastoma
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG HN004) Temporarily on Hold
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Investigator: Christopher Jones MD
Status: Active, Not Recruiting
Locally Advanced (NRG HN009)
Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG-LU008)
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (RTOG 1216)
Randomized Phase II/III Trial of Adjuvant Radiation Therapy (RT) with Cisplatin, Docetaxel Cetuximab, or Cisplatin Atezolizumab in Pathologic High Risk Squamous
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (TIGeR-PaC Study)
Multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Investigators: Deepti Behl MD, Benjamin Coombs D.O., Carlin R Hauck Radiation Oncologist, Christopher Jones MD, Brian K. Kim M.D, Charlotte D Kubicky Radiation Oncologist, Christopher J Laing M.D., Jasdeepa Nagi M.D., Hubert Y Pan Radiation Oncologist, Henal Patel M.D., Anthony T Pu Radiation Oncologist, Sivakumar Reddy M.D., Aria Sasaki M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Metastatic (NRG-BN009)
Testing the Addition of HA-WBRT to SRS in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier SRS
Investigator: Christopher Jones MD
Status: Active, Recruiting
Metastatic (NRG-BN012)
This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain.
Investigator: Christopher Jones MD
Status: Active, Recruiting